Experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin
PRODUCT PROFILE
CJC-1295 No DAC + Ipamorelin
Price range: £59.99 through £79.99
CJC-1295 No DAC + Ipamorelin is experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin. Researchers examine it in relation to short-duration GHRH-receptor and ghrelin-receptor signalling at the pituitary.
Why it is distinct
It combines two complementary upstream receptor pathways without the albumin-binding DAC group that makes CJC-1295 DAC long acting.
- Evidence stageEarly human evidence
- AvailabilityAvailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
CJC-1295 No DAC + Ipamorelin is experimental dual-secretagogue formulation combining CJC-1295 No DAC with ipamorelin. Researchers examine it in relation to short-duration GHRH-receptor and ghrelin-receptor signalling at the pituitary.
Research focus+
CJC-1295 No DAC acts through the body’s growth-hormone-releasing pathway, while ipamorelin uses a ghrelin-related pathway. Evidence for the exact combination and its long-term safety is limited.
How the mechanism differs+
CJC-1295 No DAC acts through GHRH receptors, while ipamorelin acts through the ghrelin/GHSR-1a receptor; both converge on growth-hormone release through different upstream receptors.
Evidence and limitations+
Early human pharmacology exists for related secretagogues and CJC compounds, but controlled outcome and long-term safety evidence for this exact combination is limited. It is not an authorised combined medicine.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
CJC-1295 No DAC acts through the body’s growth-hormone-releasing pathway, while ipamorelin uses a ghrelin-related pathway. Evidence for the exact combination and its long-term safety is limited.
CJC-1295 No DAC acts through GHRH receptors, while ipamorelin acts through the ghrelin/GHSR-1a receptor; both converge on growth-hormone release through different upstream receptors.
It combines two complementary upstream receptor pathways without the albumin-binding DAC group that makes CJC-1295 DAC long acting.
Early human pharmacology exists for related secretagogues and CJC compounds, but controlled outcome and long-term safety evidence for this exact combination is limited. It is not an authorised combined medicine.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability